---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-017082"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-05-14T20:36:14+00:00"
generated_at: "2026-05-14T20:38:21.267027+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Valion Bio posts Q1 net loss of $6.2M; cash falls to $7.2M; advances Entolimod

## Summary
- Net loss $6.2M ($2.23/share) vs $1.5M ($2.52/share) a year ago; operating expenses $5.6M (was $1.4M).
- Cash and equivalents $7.2M at March 31, 2026, down from $12.6M at Dec 31, 2025.
- Government engagement broadened with BARDA, NIAID, and Dept of War for Entolimod as ARS countermeasure.
- Velocity Bioworks CDMO integration advancing; facility supports internal and third-party biologics manufacturing.
- Pipeline includes Entolimod (Animal Rule pathway) and Entolasta (TLR5 agonist for oncology supportive care).

## SEC filing metadata
- accession: 0001437749-26-017082
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-05-14T20:36:14+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000143774926017082/0001437749-26-017082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000143774926017082/tivc20260405_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-017082
- JSON: https://secwatch.observer/filing/0001437749-26-017082.json
- Plain text: https://secwatch.observer/filing/0001437749-26-017082.txt

## Key facts
- Earnings Releases
  Valion Bio, Inc. reported financial results for the three months ended March 31, 2026.
  - Period: the three months ended March 31, 2026
  - Result: reported results
  source text: Valion Bio Reports First Quarter 2026 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000143774926017082/0001437749-26-017082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.